About: The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The history of monoclonal antibody development – Progress, remaining challenges and future innovations Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The history of monoclonal antibody development – Progress, remaining challenges and future innovations
Creator	Liu, Justin
source	Medline; PMC
abstract	As medicine progresses into a new era of personalised therapy, the use of monoclonal antibodies to treat a wide range of diseases lies at the heart of this new forefront. Since the licencing of the first monoclonal antibody for clinical use 30 years ago, the monoclonal antibody industry has expanded exponentially and is now valued at billions of dollars. With major advances in genetic sequencing and biomedical research, much research into monoclonal antibodies now focuses on identifying new targets for development and maximising their efficacy for use in clinical practice. However, a balance has to be struck with regards to reducing numbers of side-effects and overall economic cost, which arguably somewhat blighted their early clinical and commercial successes. Nowadays, there are approximately 30 monoclonal antibodies that have been approved for use in clinical practice with many more currently being tested in clinical trials. Some of the current major limitations include: the use of inefficient models for generation, a lack of efficacy and issues of cost-effectiveness. Some of the current research focuses on ways to improve the efficacy of existing monoclonal antibodies through optimising their effects and the addition of beneficial modifications. This review will focus on the history of monoclonal antibody development – how it has increasingly moved away from using laborious animal models to a more effective phage display system, some of the major drawbacks from a clinical and economical point of view and future innovations that are currently being researched to maximise their effectiveness for future clinical use.
has issue date	2014-09-11(xsd:dateTime)
bibo:doi	10.1016/j.amsu.2014.09.001
bibo:pmid	25568796
has license	cc-by-nc-sa
sha1sum (hex)	8cc42c8dc091b1f9333ff2b66604d54e5fc021c4
schema:url	https://doi.org/10.1016/j.amsu.2014.09.001
resource representing a document's title	The history of monoclonal antibody development – Progress, remaining challenges and future innovations
has PubMed Central identifier	PMC4284445
has PubMed identifier	25568796
schema:publication	Ann Med Surg (Lond)
resource representing a document's body	covid:8cc42c8dc091b1f9333ff2b66604d54e5fc021c4#body_text
is schema:about of	named entity 'monoclonal antibody' named entity 'REMAINING' named entity 'MONOCLONAL ANTIBODY' named entity 'HISTORY OF' named entity 'CHALLENGES' named entity 'PROGRESS' named entity 'DEVELOPMENT' named entity 'FUTURE' named entity 'bacteriophage' named entity 'half-life' named entity 'antigen' named entity 'scFv' named entity 'carbohydrates' named entity 'clinical practice' named entity 'Hybridomas' named entity 'clone' named entity 'bacterial toxins' named entity 'gene' named entity 'patient compliance' named entity 'antibodies' named entity 'chemotherapy' named entity 'spleen' named entity 'immunisation' named entity 'biotechnology' named entity 'target specific' named entity 'long-term' named entity 'antibodies' named entity 'scFv' named entity 'hypoxanthine' named entity 'lysine' named entity 'binding affinity' named entity 'HGPRT' named entity 'CD3' named entity 'monoclonal antibody' named entity 'Orthoclone OKT3' named entity 'epitopes' named entity 'expression systems' named entity 'carbohydrate' named entity 'side-effects' named entity 'antibodies' named entity 'molecular weight' named entity 'Antibody' named entity 'B-lymphocytes' named entity 'HGPRT' named entity 'complement' named entity 'genetic sequencing' named entity 'bacteriophage' named entity 'monoclonal antibodies' named entity 'ADCC' named entity 'plasmid' named entity 'scFv' named entity 'culture medium' named entity 'hybridoma' named entity 'phage display' named entity 'monoclonal antibodies' named entity 'clone' named entity 'monoclonal antibodies' named entity 'IgG' named entity 'hybridoma cells' named entity 'plasma' named entity 'monoclonal antibodies' named entity 'aminopterin' named entity 'B-lymphocytes' named entity 'guanine' named entity 'epitope' named entity 'IgG' named entity 'chronic conditions' named entity 'monoclonal antibody' named entity 'transplant rejection' named entity 'transformation efficiency' named entity 'animal species' named entity 'diseases and conditions' named entity 'PIII' named entity 'genetically engineering' named entity 'Bispecific antibodies' named entity 'tumour' named entity 'selective medium' named entity 'monoclonal antibodies' named entity 'Fc region' named entity 'effector molecules' named entity 'tumour'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software